Matches in SemOpenAlex for { <https://semopenalex.org/work/W2315140275> ?p ?o ?g. }
Showing items 1 to 60 of
60
with 100 items per page.
- W2315140275 endingPage "136" @default.
- W2315140275 startingPage "123" @default.
- W2315140275 abstract "Hepatitis C virus (HCV) has emerged as a major viral pandemic over the past two decades, infecting 170 million individuals worldwide. Egypt has the highest prevalence of hepatitis C in the world with prevalence rates of 13%- 15% of the population. Hepatitis C is characterized with its high tendency to induce chronic progressive liver damage in the form of hepatic fibrosis, cirrhosis or liver cancer. There is no vaccine against HCV infection because our understanding of the early interactions between the virus and the host immune system is still limited. The current standard of care for patients with chronic hepatitis C, pegylated interferon alpha and ribavirin combination therapy, has improved the rate of resolution of chronic hepatitis C infection. However, many patients still do not respond to therapy or develop adverse events. Moreover, the prohibitive cost of interferon-based regimen makes them inaccessible for many patients particularly in developing countries. Understanding the host and viral factors associated with viral clearance is necessary for individualizing therapy to maximize sustained virologic response rates, prevent progression to liver disease, and increase the overall benefits of therapy with respect to its costs. Host genetic diversity seems to contribute to the outcome of each phase of the clinical spectrum of HCV infection. Genome wide studies have recently showed significant associations between a set of polymorphisms in the region of the interleukin-28B (IL28B) gene and clearance of HCV in natural infection or after pegylated interferon-alfa and ribavirin treatment. This paper synthesizes the advances in pharmacogenetics of HCV infection, including the lessons learned in Egypt to date. Keywords: Hepatitis C virus, interleukin-28B polymorphisms, pegylated interferon and ribavirin, personalized medicine, pharmacogenetics, rational therapeutics, Schistosoma mansoni co-infections, Steatosis, Hepatic Fibrosis, Viral Kinetics" @default.
- W2315140275 created "2016-06-24" @default.
- W2315140275 creator A5003449905 @default.
- W2315140275 date "2011-06-01" @default.
- W2315140275 modified "2023-09-23" @default.
- W2315140275 title "Determinants of Treatment Outcomes for Hepatitis C Infection and the Path to Personalized Medicine" @default.
- W2315140275 doi "https://doi.org/10.2174/187569211795508466" @default.
- W2315140275 hasPublicationYear "2011" @default.
- W2315140275 type Work @default.
- W2315140275 sameAs 2315140275 @default.
- W2315140275 citedByCount "1" @default.
- W2315140275 crossrefType "journal-article" @default.
- W2315140275 hasAuthorship W2315140275A5003449905 @default.
- W2315140275 hasConcept C126322002 @default.
- W2315140275 hasConcept C203014093 @default.
- W2315140275 hasConcept C2522874641 @default.
- W2315140275 hasConcept C2776408679 @default.
- W2315140275 hasConcept C2776455275 @default.
- W2315140275 hasConcept C2776461080 @default.
- W2315140275 hasConcept C2777075537 @default.
- W2315140275 hasConcept C2777214474 @default.
- W2315140275 hasConcept C2780040827 @default.
- W2315140275 hasConcept C2781413609 @default.
- W2315140275 hasConcept C2908647359 @default.
- W2315140275 hasConcept C71924100 @default.
- W2315140275 hasConcept C99454951 @default.
- W2315140275 hasConceptScore W2315140275C126322002 @default.
- W2315140275 hasConceptScore W2315140275C203014093 @default.
- W2315140275 hasConceptScore W2315140275C2522874641 @default.
- W2315140275 hasConceptScore W2315140275C2776408679 @default.
- W2315140275 hasConceptScore W2315140275C2776455275 @default.
- W2315140275 hasConceptScore W2315140275C2776461080 @default.
- W2315140275 hasConceptScore W2315140275C2777075537 @default.
- W2315140275 hasConceptScore W2315140275C2777214474 @default.
- W2315140275 hasConceptScore W2315140275C2780040827 @default.
- W2315140275 hasConceptScore W2315140275C2781413609 @default.
- W2315140275 hasConceptScore W2315140275C2908647359 @default.
- W2315140275 hasConceptScore W2315140275C71924100 @default.
- W2315140275 hasConceptScore W2315140275C99454951 @default.
- W2315140275 hasIssue "2" @default.
- W2315140275 hasLocation W23151402751 @default.
- W2315140275 hasOpenAccess W2315140275 @default.
- W2315140275 hasPrimaryLocation W23151402751 @default.
- W2315140275 hasRelatedWork W1968878988 @default.
- W2315140275 hasRelatedWork W2008164329 @default.
- W2315140275 hasRelatedWork W2021484921 @default.
- W2315140275 hasRelatedWork W2034228609 @default.
- W2315140275 hasRelatedWork W2034849810 @default.
- W2315140275 hasRelatedWork W2118320797 @default.
- W2315140275 hasRelatedWork W2132275506 @default.
- W2315140275 hasRelatedWork W2161030888 @default.
- W2315140275 hasRelatedWork W57837434 @default.
- W2315140275 hasRelatedWork W83294250 @default.
- W2315140275 hasVolume "9" @default.
- W2315140275 isParatext "false" @default.
- W2315140275 isRetracted "false" @default.
- W2315140275 magId "2315140275" @default.
- W2315140275 workType "article" @default.